Although FAK itself has not been demonstrated to be an oncogene, FAK overexpression and activation have been reported in tumors of broad tissue origin [12], especially in invasive and metastatic tumors [24], including thyroid [25], prostate [26], colorectal [27], and ovary [28] cancers, as well as in malignant mesothelioma [29]. Here, PTK2 is linked to malignant mesothelioma.